DK1303269T3 - 3-substituerede oxindolderivater og deres anvendelse som KCNQ-kaliumkanalmodulatorer - Google Patents

3-substituerede oxindolderivater og deres anvendelse som KCNQ-kaliumkanalmodulatorer

Info

Publication number
DK1303269T3
DK1303269T3 DK01940246T DK01940246T DK1303269T3 DK 1303269 T3 DK1303269 T3 DK 1303269T3 DK 01940246 T DK01940246 T DK 01940246T DK 01940246 T DK01940246 T DK 01940246T DK 1303269 T3 DK1303269 T3 DK 1303269T3
Authority
DK
Denmark
Prior art keywords
potassium channel
channel modulators
oxindole derivatives
kcnq potassium
substituted oxindole
Prior art date
Application number
DK01940246T
Other languages
Danish (da)
English (en)
Inventor
Rikke L Schroeder
Dorte Stroebaek
Soeren Peter Olesen
Bo Skaaning Jensen
Original Assignee
Neurosearch As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch As filed Critical Neurosearch As
Application granted granted Critical
Publication of DK1303269T3 publication Critical patent/DK1303269T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Addiction (AREA)
DK01940246T 2000-06-29 2001-06-14 3-substituerede oxindolderivater og deres anvendelse som KCNQ-kaliumkanalmodulatorer DK1303269T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200001022 2000-06-29
DKPA200100394 2001-03-08
PCT/DK2001/000412 WO2002000217A1 (fr) 2000-06-29 2001-06-14 Utilisation de derives d'oxindole 3-substitue comme modulateurs du canal potassique kcnq

Publications (1)

Publication Number Publication Date
DK1303269T3 true DK1303269T3 (da) 2006-03-20

Family

ID=26068847

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01940246T DK1303269T3 (da) 2000-06-29 2001-06-14 3-substituerede oxindolderivater og deres anvendelse som KCNQ-kaliumkanalmodulatorer

Country Status (12)

Country Link
US (1) US20030181507A1 (fr)
EP (2) EP1634594A1 (fr)
JP (1) JP2004501192A (fr)
CN (1) CN1222288C (fr)
AT (1) ATE311879T1 (fr)
AU (2) AU7388701A (fr)
CA (1) CA2412208C (fr)
DE (1) DE60115656T2 (fr)
DK (1) DK1303269T3 (fr)
MX (1) MXPA03000032A (fr)
NZ (1) NZ522794A (fr)
WO (1) WO2002000217A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03007397A (es) 2001-02-20 2003-12-04 Bristol Myers Squibb Co Moduladores de canales de potasio kcnq y uso de los mismos en tratamiento de migrana y enfermedades mecanicamente relacionadas.
US20020183395A1 (en) * 2001-04-04 2002-12-05 Wyeth Methods for treating hyperactive gastric motility
JPWO2005035498A1 (ja) * 2003-10-08 2006-12-21 住友製薬株式会社 含窒素二環性化合物の摂食調節剤としての用途
EP1688141A1 (fr) 2005-01-31 2006-08-09 elbion AG Utilisation de flupirtine pour le traitement de la vessie hyperactive et des maladies associées et pour le traitement du syndrome du colon irritable
UA92340C2 (en) * 2005-03-03 2010-10-25 Х. Луннбек А/С Substituted pyridine derivatives
WO2007009462A2 (fr) * 2005-07-15 2007-01-25 Region Hovedstaden V/Glostrup Hospital Traitement de la migraine et des cephalees
FR2941947B1 (fr) * 2009-02-12 2011-03-25 Sanofi Aventis Derives de 3-benzofuranyl-indol-2-one subtitues en 3, leur preparation et leur application en therapeutique
FR2941946B1 (fr) * 2009-02-12 2011-03-25 Sanofi Aventis Derives de 3-benzofuranyl-indol-2-one-3-acetamidopiperazines substitues, leur preparation et leur application en therapeutique
WO2010105189A1 (fr) * 2009-03-12 2010-09-16 The Johns Hopkins University Procédé d'identification de composés atténuant la fonction ou réduisant l'abondance d'un canal potassique sensible au potentiel et étant associés au maintien de la fonction cognitive lors de la vieillesse
CA2760825C (fr) * 2009-06-03 2017-07-11 Marquette University Modulation de l'activite du canal de potassium de kcnq dans le traitement de troubles psychiatriques et de symptomes afferents
BR112013010957A2 (pt) * 2010-10-20 2016-08-30 Gruenenthal Gmbh 6-amino-nicotinamidas substituídas como moduladores kcnq2/3
WO2015197567A1 (fr) 2014-06-26 2015-12-30 F. Hoffmann-La Roche Ag Dérivés d'indolin-2-one ou de pyrrolopyridin-2-one
GB201502412D0 (en) * 2015-02-13 2015-04-01 Canbex Therapeutics Ltd Therapeutic use
CN108137555B (zh) 2015-11-06 2021-02-19 豪夫迈·罗氏有限公司 可用于治疗cns疾病的二氢吲哚-2-酮衍生物
JP6857653B2 (ja) 2015-11-06 2021-04-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｎｓ及び関連障害の治療において使用するためのインドリン−２−オン誘導体
EP3371174B1 (fr) 2015-11-06 2021-03-17 H. Hoffnabb-La Roche Ag Dérivés d'indolin-2-one
CN108349944B (zh) 2015-11-06 2021-03-30 豪夫迈·罗氏有限公司 二氢吲哚-2-酮衍生物
AU2017275657B2 (en) 2016-06-02 2021-08-19 Novartis Ag Potassium channel modulators
CN110198935B (zh) 2017-01-23 2022-05-31 卡登特治疗公司 钾通道调节剂
US20180207138A1 (en) * 2017-01-23 2018-07-26 Cadent Therapeutics, Inc. Methods for the treatment of tremors by positive modulation of sk channels
EP3585380A4 (fr) * 2017-02-24 2020-11-11 Ovid Therapeutics Inc Méthodes de traitement de troubles épileptiques
BR112021007552A2 (pt) 2018-10-22 2021-07-27 Cadent Therapeutics, Inc. formas cristalinas de moduladores de canal de potássio
EP3912625A1 (fr) 2020-05-20 2021-11-24 Kaerus Bioscience Limited Nouveaux ouvreurs de canaux potassiques maxi-k pour le traitement de troubles liés à l'x fragile

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736578A (en) * 1995-06-06 1998-04-07 Bristol-Myers Squibb Company Ethylamido fluorenes and improved method of making same
US5565483A (en) * 1995-06-07 1996-10-15 Bristol-Myers Squibb Company 3-substituted oxindole derivatives as potassium channel modulators
TW457233B (en) * 1996-10-11 2001-10-01 Bristol Myers Squibb Co Preparation of 3-fluoro oxindole derivatives
ATE342279T1 (de) * 1999-01-26 2006-11-15 Neurosearch As Kaliumkanäle und für diese kaliumkanäle kodierende gene
JP2003506388A (ja) * 1999-08-04 2003-02-18 アイカゲン インコーポレイテッド 疼痛および不安症を処置または予防するための方法

Also Published As

Publication number Publication date
AU2001273887B9 (en) 2006-02-02
JP2004501192A (ja) 2004-01-15
US20030181507A1 (en) 2003-09-25
EP1303269B1 (fr) 2005-12-07
NZ522794A (en) 2005-04-29
DE60115656T2 (de) 2006-06-14
CA2412208A1 (fr) 2002-01-03
CN1222288C (zh) 2005-10-12
EP1303269A1 (fr) 2003-04-23
CN1438885A (zh) 2003-08-27
ATE311879T1 (de) 2005-12-15
DE60115656D1 (de) 2006-01-12
WO2002000217A1 (fr) 2002-01-03
AU2001273887B2 (en) 2005-12-15
AU7388701A (en) 2002-01-08
EP1634594A1 (fr) 2006-03-15
MXPA03000032A (es) 2003-08-19
CA2412208C (fr) 2009-08-18

Similar Documents

Publication Publication Date Title
DK1303269T3 (da) 3-substituerede oxindolderivater og deres anvendelse som KCNQ-kaliumkanalmodulatorer
NO20061092L (no) Heteroarvlaminosulfonvlfenvl-derivater for anvendelse som natrium- eller kalslumkanalblokkere i behandlingen av smerte
NO20030374D0 (no) Syklopentanoindoler, preparater som inneholder slike forbindelser og behandlingsfremgangsmåter
DK1343782T3 (da) Pyrimidinaminer som angiogenesemodulatorer
NO20083220L (no) Heterocykliske derivater som modulatorer for ionekanaler
ATE472529T1 (de) Prolinamidderivate als natriumkanalmodulatoren
NO20045043L (no) Pyrimidinonforbindelser, sammensetninger og fremgangsmater
DE60225040D1 (de) Montelukast-granulatformulierung
NO20061845L (no) Fenyl-piperazinderivater som modulatorer for muskarine reseptorer
NO20074959L (no) Substituerte pyridinderivater
BRPI0414599A (pt) pirrol-indóis substituìdos
SE0203713D0 (sv) Novel compounds
NO20060402L (no) 3-amino choman og 2-aminotetralinderivater
NO20024891L (no) Farmasöytiske sammensetninger
ATE288747T1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
AU2001273887A1 (en) Use of 3-substituted oxindole derivatives as KCNQ potassium channel modulators
NO20043016L (no) 6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav
ATE542796T1 (de) N-sulfonylcarboximidamidverbindungen als apoptosepromotoren
NO20043952L (no) Benzofuran- og benzotiofenderivater som er nyttige ved behandling av hyperproliferative forstyrrelser
DK1448562T3 (da) Substituerede tetracycliske pyrroloquinolonderivater egnede som phosphodiesteraseinhibitorer
BRPI0507987A (pt) métodos e compostos moduladores receptor de glicocorticóide
DE60316128D1 (de) N-sulfonylurea-apoptosis-förderer
HUP0400063A2 (hu) Fluor-oxo-indolszármazékok mint KCNQ káliumcsatorna modulátorok, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
HRP20060403A2 (en) Indol-2-one derivatives for the treatment of central nervous disorders, gastrointestinal disorders and cardiovascular disorders
DK1459751T3 (da) (S,S)reboxetin til behandling af migrænehovedpine